Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series
- 18 February 2014
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 31 (4) , 891
Abstract
Pilot studies have shown that patients with human epidermal growth factor receptor 2-positive disease have greater risk of relapse and death. The sooner trastuzumab is administered, the greater seems to be the benefit. A delay in the initiation of adjuvant radiotherapy (RT) may result in an increased rate of local recurrence. Since limited published data exist, the aim of our analyses was to evaluate the skin and heart toxicity of concomitant treatment. Between 2003 and 2012, 95 women were treated at our Institute by concomitant therapy for clinical stage I–III invasive breast cancer. Cardiac toxicity was evaluated according to the left ventricular ejection fraction (LVEF) decrease, with a prospective monitoring program. All acute and late toxicities were assessed according to the CTCAE-v3 criteria. At a median follow-up of 4.3 years (range 1.3–10.4), 5 patients developed locoregional relapse and 7 patients developed distant metastases; disease-free survival was 90 % and overall survival 97.9 %. Overall, skin toxicity ≥Grade 2 was recorded in 13 patients (13.7 %). No dysphagia and esophagitis ≥Grade 2 were recorded. Cosmetic outcome was excellent in 41 patients (43.2 %), good in 39 patients (41.1 %), and fair in 10 patients (10.5 %). All patients concluded the programmed RT. Among the 58 patients (61.1 %) that recorded a LVEF dysfunction, the median decrease from baseline to the end of trastuzumab was 10 %, while the median decrease from baseline to the last follow-up was 7 % (p = 0.01). In our experience, concomitant trastuzumab and radiation treatment was overall well tolerated.Keywords
This publication has 49 references indexed in Scilit:
- Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancerBreast Cancer Research and Treatment, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: A single-institution studyEuropean Journal of Cancer, 2011
- Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapyBritish Journal of Radiology, 2010
- Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answersBritish Journal of Radiology, 2009
- Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831Journal of Clinical Oncology, 2009
- Concurrent chemoradiotherapy in adjuvant treatment of breast cancerRadiation Oncology, 2009
- Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoringBritish Journal of Cancer, 2009
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991